These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38369343)

  • 21. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
    Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
    Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn's Disease.
    Alric H; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
    Inflamm Bowel Dis; 2022 Feb; 28(2):218-225. PubMed ID: 33847351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological Agents in the Treatment of Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC3) Study.
    Chetwood JD; Ko Y; Pudipeddi A; Kariyawasam V; Paramsothy S; Leong RW
    Am J Gastroenterol; 2024 Aug; 119(8):1536-1544. PubMed ID: 38275272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
    Kawalec P; Moćko P
    J Comp Eff Res; 2018 Feb; 7(2):101-111. PubMed ID: 29115855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
    Sharip MT; Nishad N; Pillay L; Goordoyel N; Goerge S; Subramanian S
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673459
    [No Abstract]   [Full Text] [Related]  

  • 28. Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registry.
    Mañosa M; Fernández-Clotet A; Nos P; Martín-Arranz MD; Manceñido N; Carbajo A; Hinojosa E; Hernández-Camba A; Muñoz-Pérez R; Boscá-Watts M; Calvo M; Sierra-Ausín M; Sánchez-Rodríguez E; Barreiro-de Acosta M; Núñez-Alonso A; Zabana Y; Márquez L; Gisbert JP; Guardiola J; Sáinz E; Delgado-Guillena P; Busquets D; van Domselaar M; Girona E; Lorente R; Casas-Deza D; Huguet JM; Maestro S; Cabello MJ; Castro J; Iborra M; Cañete F; Calafat M; Domènech E;
    Dig Liver Dis; 2023 Jan; 55(1):46-52. PubMed ID: 35948459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A; Al Lehaibi LH; Alomar M; Aldhuwayan F; Alshouish S; Al-Ali AY; Almudhry Z; Almulhim A; Althagafi A; Aldosari S; AlAmeel T
    Saudi J Gastroenterol; 2024 Sep; 30(5):324-334. PubMed ID: 39157885
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
    Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
    Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab.
    Zhdanava M; Ding Z; Manceur AM; Zhao R; Holiday C; Kachroo S; Izanec J; Pilon D
    Curr Med Res Opin; 2023 Sep; 39(9):1215-1225. PubMed ID: 37563994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of vedolizumab and infliximab in biologic-naive patients with Crohn's disease: results from the EVOLVE study.
    Mantzaris GJ; Bressler B; Adsul S; Luo M; Colby C; Brett NR; Saha S; Kamble P; Wang S; Yarur A
    Eur J Gastroenterol Hepatol; 2024 Mar; 36(3):281-291. PubMed ID: 38179874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.
    Bohm M; Xu R; Zhang Y; Varma S; Fischer M; Kochhar G; Boland B; Singh S; Hirten R; Ungaro R; Shmidt E; Lasch K; Jairaith V; Hudesman D; Chang S; Lukin D; Swaminath A; Sands BE; Colombel JF; Kane S; Loftus EV; Shen B; Siegel CA; Sandborn WJ; Dulai PS;
    Aliment Pharmacol Ther; 2020 Aug; 52(4):669-681. PubMed ID: 32656800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
    Chapuis-Biron C; Kirchgesner J; Pariente B; Bouhnik Y; Amiot A; Viennot S; Serrero M; Fumery M; Allez M; Siproudhis L; Buisson A; Pineton de Chambrun G; Abitbol V; Nancey S; Caillo L; Plastaras L; Savoye G; Chanteloup E; Simon M; Dib N; Rajca S; Amil M; Parmentier AL; Peyrin-Biroulet L; Vuitton L;
    Am J Gastroenterol; 2020 Nov; 115(11):1812-1820. PubMed ID: 33156100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
    Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
    Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.
    Bressler B; Yarur A; Silverberg MS; Bassel M; Bellaguarda E; Fourment C; Gatopoulou A; Karatzas P; Kopylov U; Michalopoulos G; Michopoulos S; Navaneethan U; Rubin DT; Siffledeen J; Singh A; Soufleris K; Stein D; Demuth D; Mantzaris GJ
    J Crohns Colitis; 2021 Oct; 15(10):1694-1706. PubMed ID: 33786600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoalbuminaemia, Not Biologic Exposure, Is Associated with Postoperative Complications in Crohn's Disease Patients Undergoing Ileocolic Resection.
    Shah RS; Bachour S; Jia X; Holubar SD; Hull TL; Achkar JP; Philpott J; Qazi T; Rieder F; Cohen BL; Regueiro MD; Lightner AL; Click BH
    J Crohns Colitis; 2021 Jul; 15(7):1142-1151. PubMed ID: 33388775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stratified Patient Profiling for Vedolizumab Effectiveness in Crohn's Disease: Identifying Optimal Subgroups for Enhanced Treatment Response in the EVOLVE Study.
    Yarur A; Mantzaris GJ; Wang S; Adsul S; Kamble P; Cook E; Sajeev G; Guerin A; Bressler B
    Adv Ther; 2024 Jun; 41(6):2324-2341. PubMed ID: 38658485
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent.
    Zhdanava M; Kachroo S; Manceur AM; Ding Z; Holiday C; Zhao R; Godwin B; Pilon D
    Clin Ther; 2023 Aug; 45(8):770-777. PubMed ID: 37442653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.